|本期目录/Table of Contents|

[1]张自立,石文霞,李 霖,等.肝癌血清中miRNA-183的表达及临床意义[J].天津医科大学学报,2017,23(06):519-522.
 ZHANG Zi-li,?SHI Wen-xia,LI Lin,et al.Expression and significance of serum microRNA-183 in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2017,23(06):519-522.
点击复制

肝癌血清中miRNA-183的表达及临床意义(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
23
期数:
2017年06期
页码:
519-522
栏目:
临床医学
出版日期:
2017-11-20

文章信息/Info

Title:
Expression and significance of serum microRNA-183 in hepatocellular carcinoma
作者:
张自立123石文霞3李 霖2孟祥朝2高英堂3杜 智3
(1.天津医科大学三中心临床学院普通外科,天津300170;2.天津市第三中心医院普通外科,天津300170;3.天津市肝胆疾病研究所,天津市人工细胞重点实验室,卫生部人工细胞工程技术研究中心,天津 300170)
Author(s):

ZHANG Zi-li123?SHI Wen-xia3LI Lin2MENG Xiang-chao2GAO Ying-tang3 DU Zhi3

 

(1.Department of General Surgery,The Third Central Clinical College ,Tianjin Medical University, Tianjin 300170, China; 2. Department of General Surgery, Tianjin Third Central Hospital, Tianjin 300170, China;3.Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Artificial Cell, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin 300170, China)
关键词:
微小RNAs肝细胞癌血清miR-183
Keywords:
microRNAs hepatocellular carcinomaserummiR-183
分类号:
R735.7
DOI:
-
文献标志码:
-
摘要:

目的:比较肝癌及良性肝病患者血清中miRNA-183的表达并探讨其临床意义。方法:收集肝癌患者血清标本54例,肝硬化患者血清标本45例,肝炎患者血清标本30例及健康体检者血清标本45例,荧光定量PCR检测miRNA-183在各组中的表达量及分析肝癌组与临床病理特征之间的关系。结果:肝癌患者血清中miR-183表达量高于正常对照组,也高于肝炎组及肝硬化组(P <0.05);肝硬化组血清miR-183表达量高于正常对照组(P <0.05)。肝癌患者的血清miR-183表达量与TNM分期有关,Ⅲ~Ⅳ期的表达水平高于Ⅰ~Ⅱ期(P <0.05);低分化肝癌患者血清miR-183的表达水平高于高-中分化患者(P <0.05);伴有肝硬化的肝癌患者其血清miR-183表达水平高于不伴肝硬化者(P <0.05)。ROC曲线下面积为0.699(95% CI 0.613~0.784),最佳临界值为1.38,相应的敏感性为53.7%,特异性为83.3%,阳性预测值为60.1%,阴性预测值为76.9%。结论:血清miR-183可能作为诊断肝癌的新型肿瘤标志物,并可能预测肝癌预后。

Abstract:
Objective: To compare the expression of miR-183 in hepatocellular carcinoma(HCC) serum and benign liver diseases and explore its clinical significance. Methods: Serum miR-183 expression was measured in HCC serum(n =54), liver cirrhosis (LC) serum(n =45),chronic viral hepatitis (CH) serum(n =30) and normal controls (NC) (n =45)by quantitative real-time reverse-transcription polymerase chain reaction(qRT-PCR). Results: The expression of serum miR-183 in HCC was higher than those in normal controls, hepatitis and cirrhosis patients(P <0.05); the expression of serum miR-183 in cirrhosis patients was also higher than that in normal controls(P <0.05). The expression of serum miR-183 was higher in Ⅲ~Ⅳ stage than that in Ⅰ~Ⅱ stage in HCC(P <0.05); well-differentiated HCC was lower than that in poor-differentiated HCC (P<0.05); and HCC patients with cirrhosis had a higher expression of miR-183 than those without cirrhosis. ROC curve of serum miR-183 in HCC had an ideal diagnostic value, with a optimal value of 1.38; the diagnostic sensitivity and specificity were 53.7% and 83.3%, respectively and the positive predictive value and negative predictive value were 60.1%, 76.9% respectively. Conclusion: Serum miR-183 may act as a new tumor marker and may predict the prognosis and therapeutic effect.

参考文献/References:

[1]Zhu R X, Seto W K, Lai C L, et al. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region[J]. Gut Liver,2016,10(3):332
[2]左婷婷,郑荣寿,曾红梅,等.中国肝癌发病状况与趋势分析[J].中华肿瘤杂志,20159):691
[3]Fukuda S, Itamoto T, Nakahara H, et al. Clinicopathologic features and prognostic factors of resected solitary small-sized hepatocellular carcinoma[J]. Hepatogastroenterol, 2005,52 (64):1163
[4]Yuen M F, Cheng C C, Lauder I J, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience[J].Hepatol,2000,31(2):330
[5]Pillai R S, Bhattacharyya S N, Artus C G, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells[J].Sci,2005,309(5740):1573
[6]Barshack I, Meiri E, Rosenwald S, et al. Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression[J].Int J Biochem Cell Biol,2010,42(8):1355
[7]Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer[J].J Cancer Res Clin Oncol,2013,139(2):223
[8]Gilad S, Meiri E, Yogev Y, et al. Serum MicroRNAs are promising novel biomarkers[J].PLoS One,2008,3(9):e3148
[9]Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma[J].J Hepatol, 2012,56(1):167
[10]Xu J, Li J, Zheng T H, et al. MicroRNAs in the occurrence and development of primary hepatocellular carcinoma[J].Adv Clin Exp Med,2016,25(5):971
[11]Li J, Shi W, Gao Y, et al. Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma[J].Clin Lab,2013,59(9/10):1009
[12]Jiang L, Cheng Q, Zhang B H, et al. Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China[J].Med,2015,94(10):e603
[13]Myatt S S, Wang J, Monteiro L J, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer[J].Cancer Res,2010,70(1):367
[14]Chen L, Li Y, Fu Y, et al. Role of deregulated microRNAs in breast cancer progression using FFPE tissue[J].PLoS One,2013,8(1):e54213
[15]Zhu J, Feng Y, Ke Z, et al. Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin[J].Am J Pathol,2012,180(6):2440
[16]Liang Z, Gao Y, Shi W, et al. Expression and significance of microRNA-183 in hepatocellular carcinoma[J]. Sci World J, 2013:381874
[17]Zhang Y, Li T, Qiu Y, et al. Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma[J].Med,2017,96(2):e5642
[18]贺小停,曹秀峰.miRNA与食管癌[J].世界华人消化杂志,2007,15(19):2133

相似文献/References:

[1]周冷潇,韩 涛.慢性乙型病毒性肝炎肝硬化发生肝细胞癌的危险因素分析[J].天津医科大学学报,2017,23(03):214.
 ZHOU Leng-xiao,HAN Tao.Risk factors of hepatocellular carcinoma in patients with hepatitis B virus-related liver cirrhosis[J].Journal of Tianjin Medical University,2017,23(06):214.
[2]周冷潇,韩 涛,刘 芳.无创肝纤维化指标结合甲胎蛋白对乙型肝炎相关肝细胞癌的评估[J].天津医科大学学报,2017,23(05):415.
 ZHOU Leng-xiao,HAN Tao,LIU Fang.Assessment of non-invasive fibrosis indexes with alpha-fetoprotein?for? hepatitis B virus-related hepatocellular carcinoma[J].Journal of Tianjin Medical University,2017,23(06):415.
[3]侯振宇,孔银龙,孙 林,等.92例晚期肝细胞癌患者肝切除预后及危险因素分析[J].天津医科大学学报,2018,24(05):425.
 HOU Zhen-yu,KONG Yin-long,SUN Lin,et al.Prognosis and survival risk factors for 92 advanced hepatocellular carcinoma patients after hepatectomy[J].Journal of Tianjin Medical University,2018,24(06):425.
[4]胡 源,许戈良,荚卫东,等.C1QL1蛋白在原发性肝细胞癌中的表达及其临床意义[J].天津医科大学学报,2019,25(04):329.
 HU Yuan,XU Ge-liang,JIA Wei-dong,et al.Expressions of C1QL1 protein inprimaryhepatocellular carcinoma and its clinical significance[J].Journal of Tianjin Medical University,2019,25(06):329.

备注/Memo

备注/Memo:
作者简介 张自立(1980-), 男,硕士在读,研究方向:普通外科;通信作者:杜智,E-mail:zhi-du@163.com
更新日期/Last Update: 2017-11-14